Want to see CH:BION full AI Analyst Report?
Top Page
BB Biotech
(BION)
Select Model
Select Model
Rating:79Outperform
Price Target:
CHF64.00
▲(14.29% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by attractive valuation (very low P/E and solid dividend yield) and a strong, low-risk balance sheet. These positives are tempered by historically volatile revenue/earnings and a less steady cash-flow trajectory, while technicals add moderate support from a constructive trend and positive momentum.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet gives BB Biotech substantial financial flexibility and reduces exposure to refinancing costs. The high equity-to-assets position supports resilience through biotech market cycles and allows the company to maintain its investment strategy without material leverage pressure.
Negative Factors
Highly volatile earnings profile
BB Biotech’s earnings depend on changes in portfolio values and realized investment outcomes, so results can vary sharply between periods. The history of losses followed by a strong rebound reduces visibility and makes medium-term earnings sustainability difficult to assess.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet gives BB Biotech substantial financial flexibility and reduces exposure to refinancing costs. The high equity-to-assets position supports resilience through biotech market cycles and allows the company to maintain its investment strategy without material leverage pressure.
Read all positive factors
BB Biotech (BION) vs. iShares MSCI Switzerland ETF (EWL)
Market Cap
CHF2.70B
Dividend Yield4.55%
Average Volume (3M)79.31K
Price to Earnings (P/E)2.0
Beta (1Y)0.89
Revenue Growth45.59%
EPS GrowthN/A
CountryCH
Employees10
SectorGeneral
Sector StrengthN/A
IndustryFinancial - Conglomerates
Share Statistics
EPS (TTM)24.50
Shares Outstanding55,149,250
10 Day Avg. Volume79,858
30 Day Avg. Volume79,315
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.89
Price to Sales (P/S)32.10
P/FCF Ratio7.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.58
Revenue Forecast (FY)N/A
BB Biotech Business Overview & Revenue Model
Company Description
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of med...
How the Company Makes Money
BB Biotech makes money primarily as an investment holding company rather than by selling products or services. Its economic results are mainly driven by: (1) Net gains and losses on its portfolio: Changes in the market value of its publicly traded...
BB Biotech Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
86
Very Positive
Cash Flow
72
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 146.00M | 76.81M | 111.63M | 35.00K | 4.00K | -396.22M |
| Gross Profit | 146.00M | 76.76M | 111.63M | 35.00K | 4.00K | -396.22M |
| EBITDA | 1.35B | 578.64M | 80.33M | -34.60M | -43.01M | -59.20M |
| Net Income | 1.35B | 578.13M | 75.90M | -206.61M | -357.81M | -404.81M |
Balance Sheet | ||||||
| Total Assets | 3.09B | 2.79B | 2.41B | 2.64B | 3.05B | 3.64B |
| Cash, Cash Equivalents and Short-Term Investments | 3.08B | 99.41M | 2.41B | 2.64B | 3.05B | 3.64B |
| Total Debt | 0.00 | 0.00 | 117.50M | 304.90M | 363.00M | 355.00M |
| Total Liabilities | 5.29M | 6.97M | 121.11M | 313.94M | 367.25M | 355.00M |
| Stockholders Equity | 3.08B | 2.78B | 2.29B | 2.32B | 2.69B | 3.28B |
Cash Flow | ||||||
| Free Cash Flow | 302.78M | 309.14M | 304.56M | 218.28M | -357.81M | -94.79M |
| Operating Cash Flow | 302.78M | 309.14M | 304.56M | 218.28M | -357.81M | -94.79M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 588.94M | 0.00 |
| Financing Cash Flow | -107.09M | -203.19M | -305.20M | -220.21M | -233.27M | 91.77M |
BB Biotech Technical Analysis
Negative
56.00
Price Trends
52.89
Negative
50.10
Negative
47.26
Positive
Market Momentum
-1.07
Positive
39.47
Neutral
28.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:BION, the sentiment is Negative. The current price of 56 is above the 20-day moving average (MA) of 50.86, above the 50-day MA of 52.89, and above the 200-day MA of 47.26, indicating a neutral trend. The MACD of -1.07 indicates Positive momentum. The RSI at 39.47 is Neutral, neither overbought nor oversold. The STOCH value of 28.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:BION.
BB Biotech Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | CHF287.47B | 23.44 | ― | 2.92% | -1.06% | 30.86% | |
79 Outperform | CHF2.70B | 2.02 | 49.95% | 4.55% | 45.59% | ― | |
73 Outperform | CHF808.42M | 15.42 | ― | 8.99% | 4.74% | -28.96% | |
67 Neutral | CHF6.07B | 40.65 | 10.27% | 1.11% | 4.51% | 11.05% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | CHF1.45B | 109.81 | ― | 0.35% | 22.06% | ― | |
45 Neutral | CHF1.18B | -3.36 | ― | 86.75% | -8.06% | -87.00% |
* General Sector Average
CH:BION
BB Biotech
49.50
13.29
36.70%
CH:BSLN
Basilea Pharmaceutica
65.70
17.10
35.19%
CH:IDIA
Idorsia Ltd
4.40
0.49
12.53%
CH:BANB
Bachem Holding AG
80.90
25.86
46.98%
CH:PPGN
PolyPeptide Group AG
43.95
20.30
85.84%
CH:RO
Roche Holding Ltd
369.80
79.69
27.47%
BB Biotech Corporate Events
BB Biotech posts strong interim profit and shifts to yield-based dividend policy
Jul 24, 2026
BB Biotech AG, a specialist biotech investment company listed in Switzerland and Germany, concentrates on innovative drug developers in the U.S. and Western Europe, guided by a seasoned board and an external management team from Bellevue Asset Man...
BB Biotech posts strong Q2, boosts AI-driven investing and revises dividend policy
Jul 24, 2026
BB Biotech reported a strong second quarter of 2026, with its net asset value delivering a total return of 17.2% in CHF and outperforming the Nasdaq Biotechnology Index by 3.5 percentage points, while net profit reached CHF 451 million after a los...
BB Biotech Updates Total Voting Rights Following Capital Measure
Jun 15, 2026
BB Biotech AG has announced an updated total number of voting rights, confirming that as of June 15, 2026, the company now has 55,149,250 voting rights outstanding, with no multiple voting rights in place. The change results from a capital-related...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.